Job was saved successfully.
Job was removed from Saved Jobs.
Job Details
Novartis
Director, Early Access
Job Description
Bringing life-changing medicines to millions of people, Novartis sits at the intersection of cutting-edge medical science and innovative digital technology! As a global company, the resources and opportunities for growth and development are plentiful including global and local cross functional careers, a diverse learning suite of thousands of programs & an in-house marketplace for rotations & project work. With a strong medicines pipeline our current transformation will not just deliver growth for our business but continue to allow us to bring innovative medicines to patients quickly.
Early Access Directors are dedicated to co-developing innovative and winning market access strategies, optimizing the payer value proposition and access-relevant evidence packages for early-stage assets, in partnership with the Global TA teams.
Partnering and collaborating closely with R&D (NIBR & GDD), Strategy & Growth (S&G) and Global & US Strategic TAs, Early Access Directors will enable cross-functional teams to translate early science into compelling payer and HCS value propositions and solutions, deliver against access and payer evidence requirements and secure wide patient access and affordability. They will ensure access landscaping and payer evidence requirements are built into investment decisions, disease, and early product TPPs, clinical development plans, integrated product strategies, indication sequencing/asset maximization, and tollgate investment decisions.
Your key responsibilities:
Your responsibilities include, but are not limited to:
• Be responsible for several Novartis assets and programs alongside the early lifecycle from pre-POC to FDP, up until assets transition from the Global TA teams to the International TA teams.
• With Global TAs, co-develop Access strategies with specific focus on priority countries (US, CN, DE, JP), major HTA architypes (e.g., UK/CAN) and Budget Impact archetypes (e.g., Italy and/or Spain) needs and feasibility.
• Work in close partnership, collaborate and influence strategic TAs cross-functional teams, GPTs, S&G, Regional and priority Country teams to maximize access for early IM assets.
• With key stakeholders, co-develop and execute winning and innovative cross-functional and access strategies and solutions for several early-stage assets with specific focus on priority countries (US, CN, DE, JP), major HTA architypes (e.g., UK/CAN) and Budget Impact archetypes (e.g., Italy and/or Spain) needs and feasibility.
• Create collaborative partnerships internally and externally to break down silos; partner, collaborate and influence externally and internally across strategic TAs, GPTs, S&G, Regional and priority Country cross-functional teams to maximize access for early IM assets and to shape the future of healthcare.
• Enable cross-functional teams to translate early science into compelling payer and HCS value propositions and solutions, deliver against access and payer evidence requirements and secure wide patient access and affordability.
• Ensure access landscaping and payer evidence requirements are built into investment decisions, disease, and early product TPPs, clinical development plans, integrated product strategies, indication sequencing/asset maximization, and tollgate investment decisions. Provide access inputs into forecasting models.
• Interact with payers and relevant customer groups in priority countries, gather Region and Country-level insights and feedback, integrate into winning access and pricing strategies, incorporating payer perspective in overarching cross-functional product strategies and investment decisions
This position will be located at the East Hanover, NJ site and will not have the ability to be located remotely. This position will require 20% travel as defined by the business (domestic and/ or international). Please note that this role would not provide relocation and only local candidates will be considered.
The pay range for this position at commencement of employment is expected to be between $201,600 and $302,400 / year; however, while salary ranges are effective from 1/1/23 through 12/31/23, fluctuations in the job market may necessitate adjustments to pay ranges during this period. Further, final pay determinations will depend on various factors, including, but not limited to geographical location, experience level, knowledge, skills and abilities. The total compensation package for this position may also include other elements, including a sign-on bonus, restricted stock units, and discretionary awards in addition to a full range of medical, financial, and/or other benefits (including 401(k) eligibility and various paid time off benefits, such as vacation, sick time, and parental leave), dependent on the position offered. Details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.
Early Access Directors are dedicated to co-developing innovative and winning market access strategies, optimizing the payer value proposition and access-relevant evidence packages for early-stage assets, in partnership with the Global TA teams.
Partnering and collaborating closely with R&D (NIBR & GDD), Strategy & Growth (S&G) and Global & US Strategic TAs, Early Access Directors will enable cross-functional teams to translate early science into compelling payer and HCS value propositions and solutions, deliver against access and payer evidence requirements and secure wide patient access and affordability. They will ensure access landscaping and payer evidence requirements are built into investment decisions, disease, and early product TPPs, clinical development plans, integrated product strategies, indication sequencing/asset maximization, and tollgate investment decisions.
Your key responsibilities:
Your responsibilities include, but are not limited to:
• Be responsible for several Novartis assets and programs alongside the early lifecycle from pre-POC to FDP, up until assets transition from the Global TA teams to the International TA teams.
• With Global TAs, co-develop Access strategies with specific focus on priority countries (US, CN, DE, JP), major HTA architypes (e.g., UK/CAN) and Budget Impact archetypes (e.g., Italy and/or Spain) needs and feasibility.
• Work in close partnership, collaborate and influence strategic TAs cross-functional teams, GPTs, S&G, Regional and priority Country teams to maximize access for early IM assets.
• With key stakeholders, co-develop and execute winning and innovative cross-functional and access strategies and solutions for several early-stage assets with specific focus on priority countries (US, CN, DE, JP), major HTA architypes (e.g., UK/CAN) and Budget Impact archetypes (e.g., Italy and/or Spain) needs and feasibility.
• Create collaborative partnerships internally and externally to break down silos; partner, collaborate and influence externally and internally across strategic TAs, GPTs, S&G, Regional and priority Country cross-functional teams to maximize access for early IM assets and to shape the future of healthcare.
• Enable cross-functional teams to translate early science into compelling payer and HCS value propositions and solutions, deliver against access and payer evidence requirements and secure wide patient access and affordability.
• Ensure access landscaping and payer evidence requirements are built into investment decisions, disease, and early product TPPs, clinical development plans, integrated product strategies, indication sequencing/asset maximization, and tollgate investment decisions. Provide access inputs into forecasting models.
• Interact with payers and relevant customer groups in priority countries, gather Region and Country-level insights and feedback, integrate into winning access and pricing strategies, incorporating payer perspective in overarching cross-functional product strategies and investment decisions
This position will be located at the East Hanover, NJ site and will not have the ability to be located remotely. This position will require 20% travel as defined by the business (domestic and/ or international). Please note that this role would not provide relocation and only local candidates will be considered.
The pay range for this position at commencement of employment is expected to be between $201,600 and $302,400 / year; however, while salary ranges are effective from 1/1/23 through 12/31/23, fluctuations in the job market may necessitate adjustments to pay ranges during this period. Further, final pay determinations will depend on various factors, including, but not limited to geographical location, experience level, knowledge, skills and abilities. The total compensation package for this position may also include other elements, including a sign-on bonus, restricted stock units, and discretionary awards in addition to a full range of medical, financial, and/or other benefits (including 401(k) eligibility and various paid time off benefits, such as vacation, sick time, and parental leave), dependent on the position offered. Details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.